Discovery of Novel Inhibitors of a Critical Brain Enzyme Using a Homology Model and a Deep Convolutional Neural Network.
Source check: Needs source check. Not independent scientific confirmation.
Finding: AtomNet, a deep convolutional network, helped identify five low-micromolar ANAT enzyme inhibitors using a homology model despite the lack of a native structure or high-identity template. This is biochemical hit identification for a Canavan-disease target, not evidence of treatment efficacy.
Technology: AtomNet deep convolutional neural network
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- AtomNet, a deep convolutional neural network, ranked candidate ligands for ANAT using a homology model and informed biochemical hit selection.
- Test and result
- The primary abstract reports five low-micromolar ANAT inhibitors. Indexed ACS text describes dose-response validation and comparison of AtomNet and smina rankings over a 7.2-million-compound library; full assay denominator and comparator details were not directly reviewed.
- Limitation / still unknown
- Full ACS Methods and supporting information were not reviewed. Exact assay denominator, comparator details, cellular target engagement, in-vivo efficacy and therapeutic safety were not assessed; biochemical inhibition does not establish treatment efficacy.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://doi.org/10.1021/acs.jmedchem.0c00473
Needs source check · editorial details
The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 18 Nov 2026. Review scope: Indexed primary PubMed abstract and publication metadata; full ACS Methods/supporting information not reviewed..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.